What the FDA's peptide meeting actually changed.

You probably saw the headlines. A lot of them were loud and wrong.

Swap with a real press-pool image of the FDA meeting (or RFK Jr. at the podium) by saving one as /images/blog/fda-hero.jpg.

If you buy peptides for research, you probably saw the headlines. A lot of them were loud and wrong. Here is what the FDA's peptide meeting actually changed, why it matters for your sourcing decisions, and what people are still getting wrong about it.

What the meeting was actually about

The meeting was convened to examine the status of a specific set of peptides on the FDA's compounding lists. The agency wanted to review the safety and clinical evidence for peptides that had been available through compounding pharmacies for years.

What this is not. It is not a blanket ban on peptides. It is not a new rule that applies to research supply. It is a review of a narrow part of the regulatory map: the 503A and 503B compounding pathways that govern what US pharmacies are allowed to formulate for a named patient.

If you are a researcher, a laboratory, or a peptide supplier operating under research-use frameworks, the compounding review does not apply to your supply. It applies to the clinical-administration pathway on US soil.

What actually changed

Three things are now different in practice.

1. Compounding pharmacies in the US are operating under tighter scrutiny

Some peptides that were freely compounded for patients are now either restricted or under active review. This has created a supply gap in the US clinical market.

2. That gap has pushed demand toward non-US research supply channels

Some of that demand has gone to legitimate research suppliers. A lot of it has gone to grey-market sources with no documentation and no accountability. Buyers who previously had access through a compounding pharmacy are now ordering from suppliers whose name they cannot pronounce.

3. Regulators are paying attention to that migration

Customs enforcement of RUO shipments has increased in several jurisdictions. Buyers who do not have clear documentation of research intent are more likely to have shipments flagged.

What this means for how you should buy

The honest summary: the compounding changes do not affect whether you can buy research peptides. They affect who should be selling them to you, and what documentation should come with each order.

Three practical shifts:

• Documentation now matters more. A Certificate of Analysis that names the manufacturer, shows HPLC verification, and is traceable to a batch is no longer a nice-to-have.
• Supplier identity now matters more. An LLC with no named founders, no physical address, and no customer contact channel is a risk you did not have to take a year ago.
• Supply chain reliability now matters more. Suppliers that depend on grey-market sourcing are more exposed to enforcement than suppliers with named EU or US manufacturing partners.

What is still getting mischaracterised

A few things we see repeated in peptide communities that are worth correcting:

• "The FDA banned peptides." No. The FDA reviewed specific peptides in a specific regulatory pathway.
• "You cannot buy BPC-157 anymore." You can, through research channels, with documentation, for non-clinical use. The compounding pathway is narrower.
• "This is going to shut down the whole space." The space is not the compounding pathway. Research-use peptide supply through EU GMP facilities is a different regulatory animal.

What we are doing about it at Aevivo

Our sourcing is through an EU GMP-certified facility. Every peptide in our catalog has a Certificate of Analysis available on request. Every order is handled by a named human who can walk you through the documentation.

The regulatory environment is going to keep moving. Our job is to stay on the right side of it and make it easy for serious buyers to stay there with us.